Form 4: Director Robert J. Hariri Increases Stake in Cryoport

Director Robert J. Hariri acquired 10,350 shares of restricted stock and 16,077 stock options in Cryoport, Inc.

Summary

• Director Robert J. Hariri received a grant of 10,350 restricted stock units (RSUs) on June 5, 2026.
• The RSUs vest in full on June 5, 2027, and convert to common stock on a one-for-one basis.
• The director was also granted 16,077 stock options with an exercise price of $15.70.
• The stock options vest in 12 equal monthly installments beginning July 5, 2026, and expire on June 5, 2033.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Director alignment with shareholder interests through equity-based compensation.
• Increased beneficial ownership of company stock by a board member.

Negatives

• Dilutive impact of new equity and option grants to insiders.

Risks

• Market volatility affecting the value of equity-based compensation.
• Potential for future dilution of existing shareholders.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices intended to incentivize long-term performance and align board members with shareholder outcomes in the life sciences logistics sector.

Comparison to Industry Standards

• The use of restricted stock and options as director compensation is consistent with standard practices for publicly traded companies in the biotechnology and life sciences support industries.

Stakeholder Impact

• Minor dilution for existing shareholders due to the issuance of new equity and options.

Next Steps

• Vesting of stock options beginning July 5, 2026.
• Vesting of restricted stock units on June 5, 2027.

Key Dates

Keywords

Cryoport, CYRX, Insider Trading, Form 4, Equity Compensation, Director Ownership